Our top pick for
Building a portfolio
Corvus Pharmaceuticals, Inc is a biotechnology business based in the US. Corvus Pharmaceuticals shares (CRVS) are listed on the NASDAQ and all prices are listed in US Dollars. Corvus Pharmaceuticals employs 42 staff and has a market cap (total outstanding shares value) of USD$112.6 million.
|52-week range||USD$2.04 - USD$5.28|
|50-day moving average||USD$3.2666|
|200-day moving average||USD$3.8142|
|Wall St. target price||USD$8.63|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.559|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-32.33%|
|Return on equity TTM||-8.37%|
|Market capitalisation||USD$112.6 million|
TTM: trailing 12 months
There are currently 1.6 million Corvus Pharmaceuticals shares held short by investors – that's known as Corvus Pharmaceuticals's "short interest". This figure is 24.2% up from 1.3 million last month.
There are a few different ways that this level of interest in shorting Corvus Pharmaceuticals shares can be evaluated.
Corvus Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Corvus Pharmaceuticals shares currently shorted divided by the average quantity of Corvus Pharmaceuticals shares traded daily (recently around 1.8 million). Corvus Pharmaceuticals's SIR currently stands at 0.89. In other words for every 100,000 Corvus Pharmaceuticals shares traded daily on the market, roughly 890 shares are currently held short.
However Corvus Pharmaceuticals's short interest can also be evaluated against the total number of Corvus Pharmaceuticals shares, or, against the total number of tradable Corvus Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Corvus Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Corvus Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0678% of the tradable shares (for every 100,000 tradable Corvus Pharmaceuticals shares, roughly 68 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Corvus Pharmaceuticals.
Find out more about how you can short Corvus Pharmaceuticals stock.
We're not expecting Corvus Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Corvus Pharmaceuticals's shares have ranged in value from as little as $2.04 up to $5.28. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Corvus Pharmaceuticals's is 1.7198. This would suggest that Corvus Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and activate various immune cells, as Phase III clinical trial of CPI-006 for COVID-19. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/II clinical trial for adenosine, an immune checkpoint. Its preclinical stage products include CPI-182, an antibody to block neutrophil function and migration, and myeloid derived suppressor cells; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.